JavaScript is NOT enabled !

Engert A, Balduini C, Brand A, et al. . The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016;101:115–208. PubMed PMC

Sant M, Allemani C, Tereanu C, et al. . Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–3734. PubMed

Marcos-Gragera R, Allemani C, Tereanu C, et al. . Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica. 2011;96:720–728. PubMed PMC

Testoni M, Zucca E, Young KH, et al. . Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol. 2015;26:1069–1080. PubMed PMC

Pileri SA, Piccaluga PP. New molecular insights into peripheral T cell lymphomas. J Clin Invest. 2012;122:3448–3455. PubMed PMC

Puente XS, Pinyol M, Quesada V, et al. . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–105. PubMed PMC

US National Cancer Institute. International Lymphoma Epidemiology Consortium (InterLymph). 2021. https://epi.grants.cancer.gov/interlymph/. Accessed April 19, 2022. PubMed PMC

Beà S, Valdés-Mas R, Navarro A, et al. . Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013;110:18250–18255. PubMed PMC

Lemonnier F, Couronné L, Parrens M, et al. . Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120:1466–1469. PubMed

Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517–534. PubMed

Chubb D, Weinhold N, Broderick P, et al. . Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013;45:1221–1225. PubMed PMC

Cerhan JR, Berndt SI, Vijai J, et al. . Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014;46:1233–1238. PubMed PMC

Sant M, Minicozzi P, Mounier M, et al. . Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931–942. PubMed

Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015;136:E136–E145. PubMed

Oerlemans S, Mols F, Nijziel MR, et al. . The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors: a systematic review. Ann Hematol. 2011;90:993–1004. PubMed PMC

Gallamini A, Hutchings M, Rigacci L, et al. . Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–3752. PubMed

Radford J, Illidge T, Counsell N, et al. . Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–1607. PubMed

André MPE, Girinsky T, Federico M, et al. . Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35:1786–1794. PubMed

Fuchs M, Goergen H, Kobe C, et al. . Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, randomized phase III HD16 trial by the German Hodgkin study Group. J Clin Oncol. 2019;37:2835–2845. PubMed

Borchmann P, Plütschow A, Kobe C, et al. . PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:223–234. PubMed

Johnson P, Federico M, Kirkwood A, et al. . Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374:2419–2429. PubMed PMC

Casasnovas RO, Bouabdallah R, Brice P, et al. . PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma—Authors’ reply. Lancet Oncol. 2019;20:e190. PubMed

Borchmann P, Haverkamp H, Lohri A, et al. . Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18:454–463. PubMed

Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. . Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022;23:125–137. PubMed PMC

Bröckelmann PJ, Goergen H, Keller U, et al. . Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial. JAMA Oncol. 2020;6:872–880. PubMed PMC

Fornecker L-M, Lazarovici J, Aurer I, et al. . PET-based response after 2 cycles of brentuximab vedotin in combination with AVD for first-line treatment of unfavorable early-stage Hodgkin lymphoma: first analysis of the primary endpoint of BREACH, a randomized phase 2 trial of LYSA-FIL-EORTC Intergroup. Blood. 2017;130(suppl 1):Abstract 736.

Schmiegelow K, Attarbaschi A, Barzilai S, et al. . Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17:e231–e239. PubMed

Buchmann S, Schrappe M, Baruchel A, et al. . Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 2022;139:1785–1793. PubMed PMC

Locatelli F, Zugmaier G, Rizzari C, et al. . Effect of Blinatumomab vs Chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843–854. PubMed PMC

Gökbuget N, Dombret H, Bonifacio M, et al. . Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–1531. PubMed PMC

den Boer ML, Cario G, Moorman AV, et al. . Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2021;8:e55–e66. PubMed PMC

Peters C, Dalle JH, Locatelli F, et al. . Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295–307. PubMed PMC

Frismantas V, Dobay MP, Rinaldi A, et al. . Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129:e26–e37. PubMed PMC

Touzart A, Mayakonda A, Smith C, et al. . Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Sci Transl Med. 2021;13:eabc4834. PubMed

Enshaei A, O’Connor D, Bartram J, et al. . A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020;135:1438–1446. PubMed

Kuhlen M, Kunstreich M, Gökbuget N. Osteonecrosis in adults with acute lymphoblastic leukemia: an unmet clinical need. Hemasphere. 2021;5:e544. PubMed PMC

Gökbuget N, Dombret H, Ribera JM, et al. . International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101:1524–1533. PubMed PMC

Gökbuget N, Dombret H, Giebel S, et al. . Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019;24:337–348. PubMed

Locatelli F, Whitlock JA, Peters C, et al. . Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020;34:2473–2478. PubMed PMC

Foà R, Bassan R, Vitale A, et al. . Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613–1623. PubMed

Pocock R, Farah N, Richardson SE, et al. . Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia. Br J Haematol. 2021;194:28–43. PubMed

Wright GW, Huang DW, Phelan JD, et al. . A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551–568.e14. PubMed PMC

Sha C, Barrans S, Cucco F, et al. . Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J Clin Oncol. 2019;37:202–212. PubMed PMC

Chapuy B, Stewart C, Dunford AJ, et al. . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–690. PubMed PMC

Vitolo U, Trněný M, Belada D, et al. . Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529–3537. PubMed

Davies A, Cummin TE, Barrans S, et al. . Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649–662. PubMed PMC

Thieblemont C, Tilly H, Gomes da Silva M, et al. . Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35:2473–2481. PubMed

Poeschel V, Held G, Ziepert M, et al. . Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271–2281. PubMed

Dührsen U, Müller S, Hertenstein B, et al. . Positron emission tomography-guided therapy of aggressive Non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024–2034. PubMed

Le Gouill S, Ghesquières H, Oberic L, et al. . Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood. 2021;137:2307–2320. PubMed

Hutchings M, Morschhauser F, Iacoboni G, et al. . Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: a Phase I Trial. J Clin Oncol. 2021;39:1959–1970. PubMed PMC

Salles G, Duell J, González Barca E, et al. . Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978–988. PubMed

Morschhauser F, Flinn IW, Advani R, et al. . Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6:e254–e265. PubMed

Tilly H, Morschhauser F, Bartlett NL, et al. . Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019;20:998–1010. PubMed

Caimi PF, Ai W, Alderuccio JP, et al. . Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790–800. PubMed

Minard-Colin V, Aupérin A, Pillon M, et al. . Rituximab for high-risk, mature B-cell Non-Hodgkin’s lymphoma in children. N Engl J Med. 2020;382:2207–2219. PubMed PMC

Au-Yeung RKH, Arias Padilla L, Zimmermann M, et al. . Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group. Br J Haematol. 2020;190:753–763. PubMed

Swerdlow SH, Campo E, Pileri SA, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. PubMed PMC

Le Gouill S, Thieblemont C, Oberic L, et al. . Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–1260. PubMed

Ladetto M, Ferrero S, Evangelista A, et al. . Lenalidomide maintenance after autologous transplantation prolongs PFS in young MCL patients: results of the randomized phase III MCL 0208 trial from Fondazione Italiana Linfomi (FIL). Blood. 2018;132(suppl 1):401.

Ribrag V, Safar V, Kluin-Nelemans H, et al. . Rituximab-Lenalidomide(R2) maintenance is superior to rituximab maintenance after first line immunochemotherapy in mantle cell lymphoma: results of the MCL R2 elderly clinical trial. Blood. 2021;138(suppl 1):379.

Giné E, de la Cruz F, Jiménez Ubieto A, et al. . Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2022;40:1196–1205. PubMed PMC

Visco C, Tabanelli V, Peracchio C, et al. . Rituximab, bendamustine and cytarabine followed By venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma. Blood. 2021;138(suppl 1):2427.

Hess G, Karola W, LaRosee P, et al. . Temsirolimus in combination with bendamustine and rituximab (BeRT) for the treatment of relapsed mantle cell and follicular lymphoma: final phase I/II results. Blood. 2016;128:2977.

Jerkeman M, Eskelund CW, Hutchings M, et al. . Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5:e109–e116. PubMed

Jerkeman M, Kolstad A, Niemann CU, et al. . Venetoclax, lenalidomide and rituximab for patients with relapsed or refractory mantle cell lymphoma—data from the nordic lymphoma group NLG-MCL7 (VALERIA) phase I trial: stopping treatment in molecular remission is feasible. Blood. 2020;136(suppl 1):15.

Le Gouill S, Morschhauser F, Chiron D, et al. . Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase ½ trial. Blood. 2021;137:877–887. PubMed

Nadeu F, Martin-Garcia D, Clot G, et al. . Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136:1419–1432. PubMed PMC

Ferrero S, Rossi D, Rinaldi A, et al. . KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105:1604–1612. PubMed PMC

Eskelund CW, Dahl C, Hansen JW, et al. . TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903–1910. PubMed

Malarikova D, Berkova A, Obr A, et al. . Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers (Basel). 2020;12:E2120. PubMed PMC

Dreyling M, Ladetto M, Doorduijn JK, et al. . Triangle: autologous transplantation after a Rituximab/Ibrutinib/ara-c containing induction in generalized mantle cell lymphoma—a randomized European MCL Network Trial. Blood. 2019;134(suppl 1):2816.

Smith A, Crouch S, Lax S, et al. . Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575–1584. PubMed PMC

Dreyling M, Ghielmini M, Rule S, et al. . Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:298–308. PubMed

Pastore A, Jurinovic V, Kridel R, et al. . Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–1122. PubMed

Bachy E, Maurer MJ, Habermann TM, et al. . A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132:49–58. PubMed PMC

Huet S, Tesson B, Jais JP, et al. . A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19:549–561. PubMed PMC

Bachy E, Seymour JF, Feugier P, et al. . Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37:2815–2824. PubMed PMC

Marcus R, Davies A, Ando K, et al. . Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331–1344. PubMed

Leonard JP, Trneny M, Izutsu K, et al. . AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37:1188–1199. PubMed PMC

Heward J, Konali L, D’Avola A, et al. . KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood. 2021;138:370–381. PubMed PMC

Ortega-Molina A, Deleyto-Seldas N, Carreras J, et al. . Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. Nat Metab. 2019;1:775–789. PubMed PMC

Horton SJ, Giotopoulos G, Yun H, et al. . Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol. 2017;19:1093–1104. PubMed PMC

Bararia D, Hildebrand JA, Stolz S, et al. . Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. Cell Rep. 2020;31:107522. PubMed

Milpied P, Cervera-Marzal I, Mollichella ML, et al. . Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. Nat Immunol. 2018;19:1013–1024. PubMed

Stevens WBC, Mendeville M, Redd R, et al. . Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica. 2017;102:1413–1423. PubMed PMC

Mourcin F, Verdiére L, Roulois D, et al. . Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. Immunity. 2021;54:1901. PubMed

Araf S, Wang J, Korfi K, et al. . Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia. 2018;32:1261–1265. PubMed PMC

Mozas P, Rivero A, López-Guillermo A. Past, present and future of prognostic scores in follicular lymphoma. Blood Rev. 2021;50:100865. PubMed

Nagy Á, Bátai B, Balogh A, et al. . Quantitative analysis and monitoring of EZH2 mutations using liquid biopsy in follicular lymphoma. Genes (Basel). 2020;11:E785. PubMed PMC

Delfau-Larue MH, van der Gucht A, Dupuis J, et al. . Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. Blood Adv. 2018;2:807–816. PubMed PMC

Cascione L, Rinaldi A, Bruscaggin A, et al. . Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica. 2019;104:e558–e561. PubMed PMC

Moody S, Thompson JS, Chuang SS, et al. . Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites. Haematologica. 2018;103:1329–1336. PubMed PMC

Wu F, Watanabe N, Tzioni MM, et al. . Thyroid MALT lymphoma: self-harm to gain potential T-cell help. Leukemia. 2021;35:3497–3508. PubMed PMC

Kiesewetter B, Copie-Bergman C, Levy M, et al. . Genetic characterization and clinical features of helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma. Cancers (Basel). 2021;13:2993. PubMed PMC

Bikos V, Karypidou M, Stalika E, et al. . An immunogenetic signature of ongoing antigen interactions in splenic marginal zone lymphoma expressing IGHV1-2*04 receptors. Clin Cancer Res. 2016;22:2032–2040. PubMed

Xochelli A, Bikos V, Polychronidou E, et al. . Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. J Pathol. 2019;247:416–421. PubMed

Agathangelidis A, Xochelli A, Stamatopoulos K. A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors. J Pathol. 2017;243:403–406. PubMed

Parry M, Rose-Zerilli MJ, Ljungström V, et al. . Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21:4174–4183. PubMed PMC

Moody S, Escudero-Ibarz L, Wang M, et al. . Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma. J Pathol. 2017;243:3–8. PubMed

Thieblemont C, Cascione L, Conconi A, et al. . A MALT lymphoma prognostic index. Blood. 2017;130:1409–1417. PubMed

Conconi A, Thieblemont C, Cascione L, et al. . Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica. 2020;105:2592–2597. PubMed PMC

Zucca E, Conconi A, Martinelli G, et al. . Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35:1905–1912. PubMed

Salar A, Domingo-Domenech E, Panizo C, et al. . Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;130:1772–1774. PubMed

Kiesewetter B, Willenbacher E, Willenbacher W, et al. . A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;129:383–385. PubMed

Kiesewetter B, Lamm W, Neuper O, et al. . Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna. Hematol Oncol. 2019;37:345–351. PubMed PMC

Becnel MR, Nastoupil LJ, Samaniego F, et al. . Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019;185:874–882. PubMed PMC

Zucca E, Arcaini L, Buske C, et al. . Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:17–29. PubMed

Vannata B, Vanazzi A, Negri M, et al. . A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas. Hematol Oncol. 2021;39:60–65. PubMed

Kiesewetter B, Neuper O, Mayerhoefer ME, et al. . A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. Hematol Oncol. 2018;36:49–55. PubMed

Panayiotidis P, Follows GA, Mollica L, et al. . Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Adv. 2021;5:823–828. PubMed PMC

Iannitto E, Bellei M, Amorim S, et al. . Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol. 2018;183:755–765. PubMed

Stathis A, Gregorini A, Gressin R, et al. . IELSG-38: a phase II study of chlorambucil in combination with rituximab followed By maintenance therapy with subcutaneous rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT). Blood. 2017;130(suppl 1):1506.

Frigeni M, Besson C, Visco C, et al. . Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2020;34:1462–1466. PubMed

Ferreri AJM, Sassone M, Miserocchi E, et al. . Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. Blood Adv. 2020;4:1013–1019. PubMed PMC

Leblond V, Treon SP, Dimopoulos MA. Waldenström’s macroglobulinemia. Switzerland: Springer International Publishing; 2017.

Ouk C, Roland L, Gachard N, et al. . Continuous MYD88 activation is associated with expansion and then transformation of IgM differentiating plasma cells. Front Immunol. 2021;12:641692. PubMed PMC

Leblond V, Johnson S, Chevret S, et al. . Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31:301–307. PubMed

Treon SP, Tripsas CK, Meid K, et al. . Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372:1430–1440. PubMed

Dimopoulos MA, Tedeschi A, Trotman J, et al. . Phase 3 trial of Ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378:2399–2410. PubMed

Kurtz DM, Esfahani MS, Scherer F, et al. . Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell. 2019;178:699–713.e19. PubMed PMC

Eichhorst B, Robak T, Montserrat E, et al. . Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23–33. PubMed

Hallek M, Cheson BD, Catovsky D, et al. . iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–2760. PubMed

Zapatka M, Tausch E, Öztürk S, et al. . Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. Haematologica. 2022;107:604–614. PubMed PMC

Knisbacher B, Lin Z, Hahn CK, et al. . Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022. [In Press]. PubMed PMC

Al-Sawaf O, Zhang C, Tandon M, et al. . Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1188–1200. PubMed

International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–790. PubMed

Rawstron AC, Kreuzer KA, Soosapilla A, et al. . Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018;94:121–128. PubMed PMC

Rosenquist R, Ghia P, Hadzidimitriou A, et al. . Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017;31:1477–1481. PubMed PMC

Agathangelidis A, Chatzidimitriou A, Gemenetzi K, et al. . Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood. 2021;137:1365–1376. PubMed PMC

Minici C, Gounari M, Übelhart R, et al. . Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun. 2017;8:15746. PubMed PMC

Malcikova J, Tausch E, Rossi D, et al. . ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia. 2018;32:1070–1080. PubMed PMC

Baliakas P, Jeromin S, Iskas M, et al. . Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133:1205–1216. PubMed PMC

Tausch E, Schneider C, Robrecht S, et al. . Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135:2402–2412. PubMed

Condoluci A, Rossi D. Richter Syndrome. Curr Oncol Rep. 2021;23:26. PubMed PMC

Gribben JG, Bosch F, Cymbalista F, et al. . Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 2018;180:666–679. PubMed

Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. . COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:2354–2363. PubMed PMC

Horwitz S, O’Connor OA, Pro B, et al. . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–240. PubMed PMC

Bachy E, Camus V, Thieblemont C, et al. . Final analysis of the Ro-CHOP phase III study (Conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma. Blood. 2020;136(suppl 1):32–33. PubMed

Lemonnier F, Safar V, Beldi-Ferchiou A, et al. . Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 2021;5:539–548. PubMed PMC

Fossard G, Broussais F, Coelho I, et al. . Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715–723. PubMed

Schmitz N, Truemper L, Bouabdallah K, et al. . A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137:2646–2656. PubMed PMC

Maciocia PM, Wawrzyniecka PA, Philip B, et al. . Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23:1416–1423. PubMed

Fox CP, Civallero M, Ko YH, et al. . Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020;7:e284–e294. PubMed

Dobay MP, Lemonnier F, Missiaglia E, et al. . Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102:e148–e151. PubMed PMC

Vallois D, Dobay MP, Morin RD, et al. . Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016;128:1490–1502. PubMed

Debackere K, Marcelis L, Demeyer S, et al. . Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified. Nat Commun. 2021;12:3705. PubMed PMC

Heavican TB, Bouska A, Yu J, et al. . Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133:1664–1676. PubMed PMC

Roberti A, Dobay MP, Bisig B, et al. . Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602. PubMed PMC

McKinney M, Moffitt AB, Gaulard P, et al. . The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov. 2017;7:369–379. PubMed PMC

Laurent C, Delas A, Gaulard P, et al. . Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol. 2016;27:306–314. PubMed PMC

Laurent C, Nicolae A, Laurent C, et al. . Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. Blood. 2020;135:360–370. PubMed PMC

de Leval L. Chromosomes in breast lymphoma. Blood. 2020;136:2848–2849. PubMed

Drieux F, Ruminy P, Abdel-Sater A, et al. . Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay. Haematologica. 2020;105:1582–1592. PubMed PMC

Drieux F, Ruminy P, Sater V, et al. . Detection of gene fusion transcripts in peripheral T-cell lymphoma using a multiplexed targeted sequencing assay. J Mol Diagn. 2021;23:929–940. PubMed

Carbone A, Vaccher E, Gloghini A. Hematologic cancers in individuals infected by HIV. Blood. 2022;139:995–1012. PubMed

Carbone A, Gloghini A, Serraino D, et al. . Immunodeficiency-associated Hodgkin lymphoma. Expert Rev Hematol. 2021;14:547–559. PubMed

Ambinder RF. Epstein-barr virus-associated post-transplant lymphoproliferative disease. Recent Results Cancer Res. 2021;217:197–207. PubMed

Noy A. Optimizing treatment of HIV-associated lymphoma. Blood. 2019;134:1385–1394. PubMed PMC

Ohmoto A, Fuji S. Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders. Blood Rev. 2021;49:100807. PubMed

Shah N, Eyre TA, Tucker D, et al. . Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients—A British Society for Haematology Guideline. Br J Haematol. 2021;193:727–740. PubMed

Alderuccio JP, Olszewski AJ, Evens AM, et al. . HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021;5:2852–2862. PubMed PMC

Eyre TA, Caillard S, Finel H, et al. . Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2021;56:2118–2124. PubMed PMC

Allred J, Bharucha K, Özütemiz C, et al. . Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations. Bone Marrow Transplant. 2021;56:679–682. PubMed PMC

Munshi NC, Avet-Loiseau H, Anderson KC, et al. . A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988–5999. PubMed PMC

Zamagni E, Nanni C, Dozza L, et al. . Standardization of 18F-FDG-PET/CT according to deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116–125. PubMed

Zamagni E, Nanni C, Gay F, et al. . MRD evaluation By PET/CT according to deauville criteria combined with multiparameter flow cytometry in newly diagnosed transplant eligible multiple myeloma (MM) patients enrolled in the phase II randomized forte trial. Blood. 2019;134(suppl 1):4321–4321.

Kumar S, Paiva B, Anderson KC, et al. . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346. PubMed

Cohen AD. Myeloma: next generation immunotherapy. Hematology Am Soc Hematol Educ Program. 2019;2019:266–272. PubMed PMC

Munshi NC, Anderson LD, Jr, Shah N, et al. . Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–716. PubMed

Berdeja JG, Madduri D, Usmani SZ, et al. . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–324. PubMed

van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–427. PubMed

Gandhi UH, Cornell RF, Lakshman A, et al. . Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–2275. PubMed PMC

Chalopin T, Vallet N, Theisen O, et al. . No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. Br J Haematol. 2021;194:635–638. PubMed

Palumbo A, Bringhen S, Mateos MV, et al. . Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–2074. PubMed PMC

Corre J, Perrot A, Caillot D, et al. . del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 2021;137:1192–1195. PubMed PMC

Larocca A, Bonello F, Gaidano G, et al. . Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137:3027–3036. PubMed

Stege CAM, Nasserinejad K, van der Spek E, et al. . Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the hovon 143 study. J Clin Oncol. 2021;39:2758–2767. PubMed

Avet-Loiseau H, San-Miguel J, Casneuf T, et al. . Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39:1139–1149. PubMed PMC

Bertamini L, D’Agostino M, Gay F. MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep. 2021;16:162–171. PubMed

Abeykoon JP, Murray DL, Murray I, et al. . Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. Br J Haematol. 2021;193:380–385. PubMed

Holthof LC, Stikvoort A, van der Horst HJ, et al. . Bone marrow mesenchymal stromal cell-mediated resistance in multiple myeloma against NK cells can be overcome by introduction of CD38-CAR or TRAIL-variant. HemaSphere. 2021;5:e561. PubMed PMC

Depil S, Duchateau P, Grupp SA, et al. . ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–199. PubMed

Corre J, Munshi NC, Avet-Loiseau H. Risk factors in multiple myeloma: is it time for a revision? Blood. 2021;137:16–19. PubMed PMC

Cavo M, Gay F, Beksac M, et al. . Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456–e468. PubMed

Brown S, Sherratt D, Hinsley S, et al. ; Myeloma UK Early Phase Clinical Trial Network. MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. BMJ Open. 2021;11:e046225. PubMed PMC

D’Agostino M, Larocca A, Offidani M, et al. . Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer J. 2021;11:73. PubMed PMC

Stege CAM, Nasserinejad K, Klein SK, et al. . Improving the identification of frail elderly newly diagnosed multiple myeloma patients. Leukemia. 2021;35:2715–2719. PubMed

Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14:381–390. PubMed

Bhattacharya K, Bentley JP, Ramachandran S, et al. . Phase-specific and lifetime costs of multiple myeloma among older adults in the US. JAMA Netw Open. 2021;4:e2116357. PubMed PMC

Blommestein HM, Franken MG, van Beurden-Tan CHY, et al. . Cost-effectiveness of novel treatment sequences for transplant-ineligible patients with multiple myeloma. JAMA Netw Open. 2021;4:e213497. PubMed PMC

Borrow
RIS

Find record

In BMC

The EHA Research Roadmap: Malignant Lymphoid Diseases

Find record

Citation metrics

Archiving options